The following table details the insider trading activities
(stock purchases, stock sales, and stock option exercises) of Cassella James V since 2009.
This trader's CIK number is 1353528.
At the time of last reporting, Cassella James V was the Chief Development Officer of Concert Pharmaceuticals, Inc.. (stock ticker symbol CNCE).
Also see all insider trading activities at Concert Pharmaceuticals, Inc..
| Insider Buying | Insider Sales | Option Exercises | |||||
|---|---|---|---|---|---|---|---|
| Year | Symbol | Shares | Value | Shares | Value | Shares | Value |
| 2012 | ALXA | 0 | $0 | 60,780 | $79,298 | 0 | $0 |
| 2009 | ALXA | 0 | $0 | 24,424 | $54,430 | 0 | $0 |
| Insider Buying | Insider Sales | Option Exercises | |||||
|---|---|---|---|---|---|---|---|
| Year | Symbol | Shares | Value | Shares | Value | Shares | Value |
| 2023 | CNCE | 0 | $0 | 16,761 | $136,734 | 0 | $0 |
| 2022 | CNCE | 0 | $0 | 6,656 | $20,855 | 0 | $0 |
| 2021 | CNCE | 0 | $0 | 11,849 | $54,067 | 0 | $0 |
| 2020 | CNCE | 0 | $0 | 4,354 | $45,150 | 0 | $0 |
| 2018 | CNCE | 0 | $0 | 10,582 | $213,513 | 0 | $0 |
1. Alexza Pharmaceuticals Inc. (ALXA)
2. Concert Pharmaceuticals, Inc. (CNCE)
| Trade Date | Symbol | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2012-12-26 | ALXA | Sale | 4,558 | 4.90 | 22,315 |
| 2012-08-27 | ALXA | Sale | 10,000 | 4.14 | 41,360 |
| 2012-06-06 | ALXA | Sale | 46,222 | .34 | 15,623 |
| 2009-12-16 | ALXA | Sale | 7,732 | 2.41 | 18,610 |
| 2009-12-17 | ALXA | Sale | 4,284 | 2.20 | 9,429 |
| 2009-12-18 | ALXA | Sale | 12,408 | 2.13 | 26,391 |
| Trade Date | Symbol | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2023-02-15 | CNCE | Sale | 3,762 | 8.34 | 31,375 |
| 2023-01-30 | CNCE | Sale | 10,106 | 8.35 | 84,385 |
| 2023-01-06 | CNCE | Sale | 2,893 | 7.25 | 20,974 |
| 2022-02-14 | CNCE | Sale | 3,762 | 3.09 | 11,624 |
| 2022-01-05 | CNCE | Sale | 2,894 | 3.19 | 9,231 |
| 2021-08-16 | CNCE | Sale | 8,086 | 3.28 | 26,522 |
| 2021-02-16 | CNCE | Sale | 3,763 | 7.32 | 27,545 |
| 2020-08-17 | CNCE | Sale | 4,354 | 10.37 | 45,150 |
| 2018-04-17 | CNCE | Sale | 10,582 | 20.18 | 213,513 |
Insider trading activities including stock purchases, stock sales, and option exercises listed in the above table cannot be completely guaranteed as to their accuracy. For more information regarding the trades made by Cassella James V (Chief Development Officer of Concert Pharmaceuticals, Inc. at the time of this reporting) see the Securities and Exchange Commission (SEC) website.